Gout is an inflammatory disease manifested by the deposition of monosodium urate (MSU) crystals in joints, cartilage, synovial bursa, tendons or soft tissues. Gout is not a new disease, which was first documented nearly 5,000 years ago. The prevalence of gout has increased globally in recent years, imposing great disease burden worldwide. Moreover, gout or hyperuricemia is clearly associated with a variety of comorbidities, including cardiovascular diseases, chronic kidney disease, urolithiasis, metabolic syndrome, diabetes mellitus, thyroid
dysfunction, and psoriasis. To prevent acute arthritis attacks and complications, earlier use of pharmacotherapeutic treatment should be considered, and patients with hyperuricemia and previous episodes of acute gouty arthritis should receive long-term urate-lowering treatment. Urate-lowering drugs should be used during the inter-critical and chronic stages to prevent recurrent gout attacks, which may elicit gradual resolution of tophi. The goal of urate-lowering therapy should aim to maintain serum uric acid (sUA) level <6.0 mg/dL. For patients with tophi, the initial goal can be set at lowering sUA to <5.0 mg/dL to promote tophi dissolution. The goal of this consensus paper was to improve gout and hyperuricemia management at a more comprehensive level. The content of this consensus paper was developed based on local epidemiology and current clinical practice, as well as consensuses from two multidisciplinary meetings and recommendations from Taiwan Guideline for the Management of Gout and Hyperuricemia.
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Gout is a modern-day disease caused either by reduced excretion (70-90%) or increased production (10-30%) of uric acid that results in elevated serum uric acid (sUA) levels. It is an inflammatory disease manifested by the deposition of monosodium urate (MSU) crystals in joints, cartilage, synovial bursa, tendons or soft tissues. Gout is prevalent in men of middle-age and women after menopause; overall, men comprise 90-95% of the gout population. Acute gout attack is characterized by sudden onset of redness, swelling, warmth and pain in the joints, predominantly those of the lower limbs. Hyperuricemia, defined as a sUA level > 7.0 mg/dL, is the most dominant factor in gout development. The chance of gout development is correlated with sUA levels, as well as the duration of sUA elevation. However, the majority of the hyperuricemic individuals is and remains asymptomatic through their lives and only around 10% of them eventually develop gout. Giving that approximately one-third of patients have normal sUA levels during acute flare of gouty arthritis, patient history, clinical manifestation, disease course, and triggering factors should all be considered in differential diagnoses. Gout diagnosis can be confirmed by joint fluid examination and identification of needle-shaped, phagocytosed MSU crystals in the synovial fluid aspirated during acute flares.
The prevalence of gout has increased globally in recent years, imposing great disease burden worldwide. 1 According to Taiwan's National Health Insurance (NHI) Research Database, the estimated prevalence (based on International Classification of Diseases-9 definition) and incidence of gout in Taiwan was 6.24% and 2.74 per 1000 person-years in 2010, respectively. 2 In a recent nationwide survey (the Nutrition and Health Survey in Taiwan), researchers reported gout prevalence to be 8.2% in men and 2.3% in women in the period from 2005 to 2008, 3 which is close to the estimates for 2004 based on the information derived from the National Health Insurance Research Database (NHIRD). 4 Nevertheless, new treatment agents have transformed the treatment strategies for gout and hyperuricemia. While the inflammatory mechanism of gout has become better understood, evidence supporting the association of gout and hyperuricemia with a wide variety of disorders has grown more compelling. In light of these recent advancements and the fact that comorbidities are highly prevalent in patients with gout or hyperuricemia, two multidisciplinary meetings were held in 2016 to facilitate dynamic exchanges of clinical experience and expertise among medical professionals from the fields of allergy, immunology, rheumatology, cardiology, endocrinology, and nephrology in Taiwan. Systematic literature searches were conducted by KY, JC and TH using MEDLINE, PubMed, EMBASE, Cochrane Central Register of Controlled Trials and manual searches of the reference lists of the selected articles. Members of the guideline working group were asked to give an extensive discussion and deliberation for the management of gout based on available research evidence and their own clinical expertise after reviewing the published recommendations.
METHODS
Prior to the formulation of the 2016 multidisciplinary consensus recommendations, the evidence generated by the TRA was reviewed by a representative panel of nine rheumatologists together with two cardiologists, one nephrologist, one endocrinologist and one general practitioner, who are experts in gout and hyperuricemia, from 12 hospitals around Taiwan to create local recommendations relevant to the diagnosis and management of gout in this country. Finally, the moderators selected 14 key clinical questions pertinent to the diagnosis and management of gout based on previous versions of the TRA gout guideline and discussions through e-mail or physical meetings for gout and hyperuricemia. Owing to time constraints, one final recommendation was determined via an e-mail survey of all rheumatologists who participated in the meeting for TRA guideline production. Individual statements for the 14 clinical questions with level of evidence, grade of recommendation, and level of agreement were developed. The level of evidence and grade of recommendation were scored using the Oxford Centre for Evidence-based Medicine Level of Evidence (2011). 5 The level of evidence (LoE) in support of each recommendation was determined ((i) meta-analysis of randomized controlled trials; (ii) randomized trials or observation studies with dramatic effect; (iii) nonrandomized trial controlled cohort/follow-up studies; (iv) case series, case-control studyies or historically controlled studies; (v) mechanism-based reasoning). 5 The grade of recommendation (GoR) was determined (A: consistent level 1 studies; B: consistent level 2 or 3 studies, or extrapolations from level 1 studies; C: level 4 studies or extrapolations from level 2 or 3 studies; D: level 5 evidence or inconsistent or inconclusive studies of any level). 5 Subsequently, a modified Delphi exercise was conducted to determine the level of agreement of each statement. Agreement relates to the entire statement for each recommendation and was voted on a scale from 0 to 10 (0, completely disagree; 10, fully agree).
1. Hyperuricemia Is a Major Risk Factor for Gout ([LoE: 3; GoR: B; Agreement: 9.80 AE 0.40)
Hyperuricemia is a major risk factor for gout. The association between hyperuricemia and gout incidence rate has been reported in the Normative Aging Study; 6 with a sUA level < 7.0, 7.0-8.9 and ≥ 9.0 mg/dL, the annual incidence rate of gout was estimated to be 0.1%, 0.5% and 4.9%, respectively. In a retrospective report, the odds ratio for a gout flare in British gout patients with a sUA level of 6.0-7.0, 7.0-8.0, 8.0-9.0 and ≥ 9.0 mg/dL was 1.33, 1.49, 1.71 and 2.15, respectively, compared with those in whom sUA levels were < 6.0 mg/dL. 7 Although hyperuricemia has been identified as the key risk factor for gout, gouty arthritis only develops in one-tenth of the hyperuricemic patients in clinical observations. Cardiovascular diseases A significant correlation between hyperuricemia and cardiovascular diseases has been demonstrated in an ample amount of studies. For instance, elevation of sUA level has been shown to be significantly associated with both coronary heart diseases (CHD) and heart failure. 10 Even for patients at low risk for atrial fibrillation, hyperuricemia could considerably increase the risk of stroke, indicating that it was also an independent risk factor for stroke for this specific subgroup.
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In an American study, male gout patients were reported to experience a 60% excess of CHD and develop angina pectoris twice as often than those without gout. 12 Compared with gout-free patients, the risk of all-cause and cardiovascular mortality in male gout patients was increased by 28% and 55%, respectively. 13 In 2015, analyses of Taiwan's NHI Research Database revealed that gout patients had a 66% greater risk of deep vein thrombosis (DVT), and a 53% increased risk of pulmonary embolism (PE), compared with gout-free patients. Moreover, for gout patients who do not receive urate-lowering agents, their risks of DVT and PE are drastically increased, with a hazard ratio of 2.16 and 2.28, respectively.
14 A nationwide cohort study from Taiwan also found that gout patients had a greater risk of erectile dysfunction relative to the general population. 15 
CKD and nephrolithiasis
In a meta-analysis, gout was proven to be an independent risk factor for CKD (relative risk [RR] = 2. 41) and nephrolithiasis (RR = 1.77), and the authors thus recommended that gout patients should undergo regular screenings for CKD. 16 Research has shown that hyperuricemia may cause kidney damage, thereby accelerating CKD progression. Studies have also demonstrated that urate-lowering agents can have protective effects on renal function in asymptomatic hyperuricemic patients; 17, 18 however, the specific underlying mechanism awaits further illustration. 19 On the other hand, the prevalence of gout in CKD patients was also higher than that of the general public. 20 Hyperuricemia was a risk factor for all-cause and cardiovascular mortality in patients with CKD stages 3-5. 21 
Metabolic syndrome
The recent increase in hyperuricemia and gout prevalence may be associated with the surging rates of obesity and metabolic syndrome in recent decades. 7, 22, 23 In 2013, a report from Taiwan showed that gout incidence rate was increased when hyperuricemia was comorbid with certain metabolic disorders (e.g., hypertension, obesity and hyperlipidemia). 22 Metabolic syndrome is universally a valuable indicator for gout attack in male patients. The risk of gouty arthritis flare in male patients with metabolic syndrome was increased by around 37% even when their sUA levels lie within the normal ranges. 22 However, such correlation was less conspicuous in female patients. 22 The significant association between sUA level and metabolic syndrome was established in two studies in 2015. 10, 23 By enrolling patients with dyslipidemia, one of these studies found that patients with highest sUA category (men: > 7.1 mg/dL [> 420 lmol/L]; women: > 6.1 mg/dL [> 360 lmol/L]) had a significantly higher risk of developing metabolic syndrome, compared with those with lowest sUA category (men: < 4.7 mg/dL [< 280 lmol/L]; women: < 3.9 mg/dL [< 230 lmol/ L]). 10 A similar observation was reported in the other Taiwanese local study: compared with individuals with sUA < 7 mg/dL, the risk of developing metabolic syndrome was five times higher among those with sUA > 9 mg/dL. 23 
Diabetes mellitus
As shown in studies, sUA level was not only associated with the risk of diabetes, it was also an independent predictive factor for diabetes complications (e.g., neuropathy, retinopathy, kidney diseases, diabetes mellitus foot and vasculopathy). 24 Thyroid dysfunction An article published in 2014 revealed that gout incidence was significantly higher in patients with hyperthyroidism or hypothyroidism than those with normal thyroid function. 25 
Psoriasis
Compared with those without psoriasis, psoriasis patients were at a higher risk of hyperuricemia (RR = 1.37) and gout (RR = 1.83). However, evidence remains inadequate to demonstrate whether psoriasis could be an independent risk factor for gout and hyperuricemia. Based on the pathophysiology of gout, the physiochemical definition of hyperuricemia should be defined as a sUA level > 6.8 mg/dL for adults. 27, 28 Gout is a disorder that manifests as a spectrum of clinical and pathological features built on a foundation of an excess body burden of uric acid, manifested in part by hyperuricemia, which is defined as a serum urate level greater than 6.8 mg/dL. 28 For easier memorization, a serum urate level above 7.0 mg/dL is considered abnormal in this document. For individuals with a sUA level between 7 and 8 mg/dL, detailed patient history and further physical examination should be performed to confirm the presence of associated disorders such as gout, hypertension, diabetes, obesity and metabolic syndrome (Table 1) . Although hyperuricemia is usually asymptomatic, it is imperative for physicians, nurses, pharmacists, physical therapists and nutritionists to conduct in-depth investigations. Hopefully such active measures can facilitate early diagnosis, treatment and prevention of the associated diseases before the target organs are functionally damaged. Hyperuricemia is merely a biochemical disorder. Restoration of sUA levels to normal ranges is possible either by adopting lifestyle changes such as increased exercise activity, fluid intake and diet adjustment, or identifying and rectifying the causes of hyperuricemia. However, if hyperuricemia persists, the possibility of gout significantly increases with sUA concentration. Notably, the majority of patients with hyperuricemia (90%) may not experience gout attacks, 6, 8, 9, 29 especially in those with slightly elevated sUA levels. In addition to high sUA levels, the risk factors for gout include obesity, weight gain, drinking habits, hypertension, renal impairment, family history of gout and use of diuretics. 30, 31 While asymptomatic hyperuricemia does not require immediate urate-lowering treatment, potential causes of hyperuricemia should be identified and properly managed (Table 1) , especially in cases where metabolic syndrome-associated diseases may potentially increase cardiovascular risks. The use of medication such as aspirin, alcohol, diuretics, anti-tuberculosis drugs, cyclosporine 32 and chemotherapy agents may lead to elevated sUA levels in a minority of cases. The initial phase of an acute gouty arthritis often involves a single joint, and the main clinical manifestations are characterized by intense joint pain, redness, swelling, warmth and pain in the joint and surrounding soft tissues. Fever and arthritis attack in multiple joints may occur in later phases. Gout attacks are characterized by the sudden onset of pain, frequently at midnight or before dawn, and some patients may experience premonitions such as slight or stinging pain. 27, 33, 34 The pain peaks within 1-2 days and usually subsides within 3-10 days even without treatment but may last, although rarely, for a couple of weeks. 27, 34, 35 Acute gouty arthritis commonly involves the lower distal joints, and the joints most frequently affected in the initial attacks are the first metatarsophalangeal joints, followed by the ankle joints and knee joints. If the sUA level persistently remains above normal ranges, the frequency of acute gouty arthritis generally increases along with time, as crystals may form and precipitate within articular cavities after a period of time. The gout classification criteria were updated by ACR and EULAR in 2015, 38 in which the entry criterion was defined as 'at least 1 episode of swelling, pain, or tenderness in a peripheral joint or bursa'. Therefore, these classification criteria should not be applied to patients without previous episodes of joint swelling and pain. For patients who previously experienced joint pain and fulfilling the sufficient criterion defined as 'presence of MSU crystals in a symptomatic joint or bursa (i.e., in synovial fluid) or tophus', further scoring is not required. If the aforementioned sufficient criterion is not met (the most frequent situation being the lack of synovial microscopy results), scoring of the parameters in clinical, laboratory and imaging domains are then computed to determine whether the individual has gout. Individuals with a score ≥ 8 are classified as having gout ( To date, the presence of phagocytosed MSU crystals confirmed by microscopy analysis of synovial fluid remains the gold standard for diagnosing gout. However, the presence of MSU crystals varies during the course of a gout attack, making microscopy analysis of synovial fluid a test with low sensitivity but excellent specificity. Therefore, even for patients who received a gout diagnosis based on the scoring system, 38 synovial fluid should be aspirated in subsequent acute attacks to confirm diagnosis and facilitate differential diagnosis. Even if MSU crystals are detected in the polarized light microscopy analysis of synovial fluid, the possibility of concomitant gout and septic arthritis should not be overlooked. 36, 37 Hence, when bacterial infection in the joint is suspected, Gram stains and bacterial culture of the synovial fluid should be performed. For these reasons, differential diagnosis of gout sometimes involves close examination of patient history, gout flare history, clinical manifestations, disease course and triggering factors, in combination with clinical experience. While the significance of imaging has increased with the rapidly advancing testing technology, none of the imaging tests alone could confirm the diagnosis of gout. To date, diagnoses should still be made based on the 2015 ACR/EULAR classification criteria ( An arthritis flare in patients with high sUA levels may not necessarily be an episode of gout attack. Around one-third of patients have normal sUA levels during acute flares. 34 Moreover, a broad spectrum of diseases can also cause joint disorders with features of redness, swelling, warmth and pain. In order to make correct judgments and differential diagnosis of gout, detailed history, physical examination, synovial fluid analysis or tissue biopsy, as well as blood biochemistry tests, should be performed. 34, 38 The list of differential diagnoses should include cellulitis, palindromic rheumatism, septic arthritis, pseudogout, seronegative spondyloarthropathy, rheumatoid arthritis and degenerative arthritis. Based on disease stage (i.e., acute and chronic), pharmacotherapy of gout can be further classified into two main categories. Since the medications used in the respective stages are largely different, it is imperative for patients to understand when to take a particular drug. For example, when suffering from acute pain, antiinflammatory painkillers and/or colchicine should be taken, whereas urate-lowering drugs would not be beneficial. Contrarily, urate-lowering drugs should be used during the inter-critical and chronic stages to maintain sUA level < 6.0 mg/dL to prevent recurrent gout attacks, [39] [40] [41] [42] [43] and perhaps to elicit gradual resolution of tophi (Fig. 1) . It is important to consider that many Step 1 -Entry criteria: ≥ 1 episode of swelling, pain, or tenderness in a peripheral joint/bursa
Step 2 -Sufficient criterion: Presence of monosodium urate (MSU) crystals in a symptomatic joint, bursa, or tophus. (If yes, diagnosis is positive)
Step 3 -Classification criteria (≥ 8 scores required for positive diagnosis) ≥ 8 points: gouty arthritis is very likely. †To convert serum urate mg/dL to mmol/L, multiply by 59.48. Modified from 2015 ACR-EULAR Gout Classification Criteria. 38 MTP, metatarsophalangeal joint; DECT, dual-energy computed tomography; MSU, monosodium urate.
gout patients are not adequately treated in Taiwan as revealed by the high prevalence of tophi in gout patients 35 and to highlight the burden of gout and hyperuricemia. Thus, we selected the Japanese guideline 41 algorithm as our model. Moreover, ample patient education should be provided in areas such as lifestyle changes, benefits of medication and treatment adherence. Use of unapproved agents/treatments should be prohibited. Acute gouty arthritis generally resolves spontaneously within 1-2 weeks without anti-inflammatory treatment and rarely persists over 2 weeks. Nonetheless, earlier use of anti-inflammatory painkillers can provide rapid pain relief. 44 Therefore, upon perceiving signs of pain, the earlier anti-inflammatory painkillers are administered, the better pain-relief response can be delivered, along with the benefits of reduced duration of acute gouty arthritis and medication dosage. Alternatively, applying ice locally may be considered as a supportive measure for pain relief. 45 Depending on comorbidities, three types of anti-inflammatory painkillers are generally prescribed in the treatment of acute gouty arthritis (Table 3) . Gout flares are often treated with some combination of steroids, non-steroidal antiinflammatory drugs (classically, indomethacin), opioids for extreme pain, adrenocorticotropic hormone and colchicine, depending on the patient's age and other risk factors for complications. 34, 44 Given that rapid changes in sUA levels may provoke the onset of acute gouty arthritis, introduction or discontinuation of urate-lowering agents is ill-advised during an acute gout attack. Currently, gout patients with hyperuricemia are primarily managed by pharmacotherapeutic agents. However, the consensus on when to initiate long-term urate-lowering treatment as a lifelong prophylaxis remains lacking. [41] [42] [43] [46] [47] [48] To prevent acute arthritis attacks and complications, numerous experts have suggested that pharmacotherapeutic treatment should be started earlier, 41 and patients with hyperuricemia and previous episodes of acute gouty arthritis should receive longterm urate-lowering treatment. Long-term/lifelong urate-lowering therapy is generally recommended, even after the cessation of acute arthritis attacks. The goal of urate-lowering therapy should be set to maintain sUA levels < 6.0 mg/dL. [39] [40] [41] [42] [43] 46, 49 Surgical intervention should be reserved for cases where the tophus causes joint destruction/deformity, severe pain, nerve compression, (increased risk of) infection or joint motion restriction. 50, 51 For patients with tophi, the initial goal can be set at lowering sUA to < 5.0 mg/dL to promote tophi dissolution. [39] [40] [41] [42] [43] 46, 49 Urate-lowering drugs can be primarily classified into two types, that is xanthine oxidase inhibitors (XOI) and uricosuric agents. The former group includes allopurinol and febuxostat, 52 whereas the latter includes benzbromarone and sulfinpyrazone (Table 4) . While XOI is the first choice in Western countries, allopurinol could cause severe hypersensitivity reactions in Taiwanese patients. 53 Therefore, Corticosteroid can be an acute/short-term treatment alternative for patients who are ineligible for NSAID and colchicine.
Acute Gouty Arthritis Generally Resolves

The Recommended Goal of
NSAID, nonsteroidal anti-inflammatory drug; COX, cyclooxygenase; CCr, creatinine clearance (mL/min); i.v., intravenous; ACTH, adrenocorticotropic hormone; i.m., intramuscular.
prior to selecting and administering urate-lowering drugs, liver and renal functions, as well as other background factors should all be considered. Since uricosuric agents only increase uric acid excretion and do not affect uric acid production, they are not indicated for the following conditions: (i) hyperuricemia caused by uric acid overproduction; (ii) patients with renal insufficiency, as uricosuric agents offer limited efficacy in this circumstance (e.g., avoid prescribing sulfinpyrazone when creatinine clearance [CCr] is < 30 mL/min); and (iii) urolithiasis with uric acid composition, as there is an increased risk of urolithiasis and uric acid nephropathy. 39 To prevent uric acid urolithiasis, uricosuric agents should be started at a lower dose, together with sufficient water intake.
Allopurinol (100, 300 mg/tablet) This is a XOI that disrupts the purine catabolism, thereby lowering both serum and urinary uric acid concentrations. Allopurinol is generally prescribed for preventing gout attack, nephrolithiasis, and chemotherapy-induced hyperuricemia. Common side effects of allopurinol include rash and gastrointestinal (GI) discomfort. The half-life of allopurinol and its major metabolite oxypurinol is 1-3 h and 17-40 h, respectively. Consequently, allopurinol can be taken once daily. Allopurinol dose adjustment should be based on the patient's renal function (i.e., CCr). Considering that allopurinol is effective in treating both uric acid overproduction and underexcretion, it is frequently prescribed in urate-lowering therapies. Allopurinol is generally very well-tolerated with low incidence of side effects. However, allopurinol hypersensitivity syndrome (AHS) can progress from mild rash to severe hypersensitivity reactions, including skin and mucosal necrosis, Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatic necrosis and renal impairment. The onset of severe cutaneous adverse reactions (SCARs)/severe hypersensitivity largely varies, ranging from 1-728 days (47 days in average) after administration, contributing to a 20-25% mortality rate. Renal insufficiency and age (> 60 years old) appear to be two major factors associated with SCARs. One Taiwanese study published in 2015 retrospectively analyzed the NHI research database and found that the AHS incidence, hospitalization and mortality rate associated with AHS among new users was 0.468%, 0.202% and 0.039%, respectively. Moreover, patients with renal or cardiovascular diseases had an even higher AHS incidence and related mortality rate. 53 Thus, despite that allopurinol is indicated in the following indications/subgroups, it should be used with caution: (i) gouty tophi; (ii) uric acid overproduction (uric acid excretion > 800 mg/24 h under regular diet); (iii) patients who are poor candidates for uricosuric drugs, for example intolerance, renal dysfunction or drug inefficacy; (iv) history of uric acid urolithiasis; (v) cancer patients undergoing chemotherapy (in risk of acute hyperuricemia-induced renal diseases). 39 For patients with normal renal function, the recommended starting dose is 100 mg/day. If no allergic reaction is observed after 1 month of treatment, dose escalation can be considered. The maximum dose is 800 mg/day, and the regular dose is 300 mg/day. Since oxypurinol may accumulate in the kidneys, dose adjustment should be based on renal function for patients with renal dysfunction. The use of allopurinol in human leukocyte antigen (HLA)-B*5801 allele carriers is associated with increased risk of SCARs. Considering that the implementation of prospective HLA-B*5801 genotyping combined with alternative treatment plans has been shown to help lower the risk of SCARs, 54 physicians may perform HLA-B*5801 genotyping prior to prescribing allopurinol. Nevertheless, SCARs can occur in HLA-B*5801 negative patients. Therefore, allopurinol should be used with caution, irrespective of the patient's HLA-B*5801 status. Caution should be exercised when combining allopurinol with other drugs as there may be increased risk of AHS. For example, combination use of allopurinol with ampicillin, thiazide-like diuretics, or angiotensin-converting-enzyme inhibitors may be a risk factor for AHS. Patients allergic to allopurinol may be referred to rheumatologists for further evaluation and treatment. Warfarin users should beware of bleeding. Furthermore, allopurinol dosage should be reduced when used in combination with azathioprine or mercaptopurine.
Febuxostat (80 mg/film-coated tablet) Different from allopurinol in chemical structure, febuxostat is a non-purine XOI, and thus does not affect the enzyme activities involved in purine or pyrimidine metabolism. Being an XOI, febuxostat is efficacious in treating both overproduction and underexcretion of uric acid. 55 Since febuxostat is mainly excreted by the liver, dose adjustment is not necessary for patients with mild to moderate renal impairment. The Taiwan Ministry of Health and Welfare has approved the use of febuxostat in patients with mild to moderate liver and renal impairment without dose adjustment. The starting dose is 40 mg daily, and can be increased to 80 mg For patients who do not achieve a sUA level < 6.0 mg/dL after 2 weeks with 40 mg once daily, 80 mg once daily is recommended.) A cost-effectiveness study showed that febuxostat can help more patients maintain a sUA level < 6.0 mg/dL compared with allopurinol, and in turn reduces the risk of gout attack and CKD, and thus may be a preferred option especially for patients with CKD stages 3/4. 56 Moreover, febuxostat has been listed as an available choice for patients with urolithiasis in Taiwan' NHI policy since 2016. The rate of side effects with febuxostat is generally low, and the common side effects are GI symptoms (e.g., nausea, vomiting, diarrhea, abdominal pain). Less common side effects are liver function abnormalities, headache and arthralgia. Physicians should observe signs of cardiovascular disease and monitor liver function. Given that febuxostat is structurally different from allopurinol, reports of febuxostat-related SCARs are extremely rare in published studies.
Benzbromarone (50, 100 mg/tablet or capsule) Benzbromarone is taken orally once daily, usually at the dose of 50 mg/day. The maximum daily dosage should not exceed 100 mg. Use of benzbromarone should be avoided when CCr falls below 20 mL/min for its lack of efficacy. In view of the few cases of fulminant hepatitis reported worldwide, 57 Taiwan Ministry of Health and Welfare has requested a warning about hepatotoxicity to be added to the product labeling, as well as periodic liver function tests in the first 6 months of treatment. Patients should be advised to interrupt treatment and seek immediate medical attention upon the occurrence of symptoms indicative of hepatic adverse event (e.g., anorexia and generalized malaise). However, serious hepatitis has not yet been reported in Taiwan. Moreover, uricosuric agents are relatively contraindicated in patients with urolithiasis. 42 Uric acid clearance at baseline may help select suitable candidates for uricosuric treatment. To avoid uricosuric-induced urolithiasis, proper urinary tract management including adequate fluid intake and, if necessary, urine alkalinization should be instituted.
Sulfinpyrazone (100 mg/tablet or capsule) This is a uricosuric agent that also possesses antiplatelet effects. The starting dose of sulfinpyrazone is usually 50-100 mg twice daily via oral administration. The common daily dose is 300-400 mg and may increase up to 800 mg in 2-3 divided doses. Side effects include GI discomfort, rash and uric acid urolithiasis. Although adverse events of anemia, leukopenia, thrombocytopenia and agranulocytosis have been rare, routine complete blood count tests for patients receiving sulfinpyrazone are recommended. Sulfinpyrazone may inhibit metabolism of sulfonylurea drugs, leading to hypoglycemia. Individuals concomitantly taking warfarin should observe signs of bleeding, as sulfinpyrazone may have inhibitory effects on platelets. Research has suggested that dietary management can only lower sUA level by roughly 1.0 mg/dL. 58 Hence, medication is needed to effectively lower sUA levels for the majority of patients. Medication dosage may be reduced if low-purine diet is integrated as part of the daily diet. The purine contents of fruits, vegetables and dairy products, as well as starch (e.g., grains and potato) are relatively low. 59 The intake of seaweed, protein (e.g., internal organs), and seafood should be limited for their relatively high purine content. Sea cucumber and jellyfish are the few low-purine seafood choices that gout patients may consume. While fat and oil do not affect sUA levels, they may The recommended goal of urate-lowering therapy is to maintain sUA levels < 6.0 mg/dL. For patients with tophi, the preliminary goal can target to lowering sUA levels to < 5.0 mg/dL to promote tophi dissolution. Liver and renal function, as well as other background factors should be carefully weighted prior to selecting and administering the most fitting uratelowering agents. Long-term/lifelong urate-lowering therapy is generally recommended 3 B 9.30 AE 0.56
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Dietary control can only lower sUA levels by roughly 1.0 mg/dL and generally cannot help reduce sUA levels to < 6.0 mg/dL. Therefore, urate-lowering agents are needed to effectively lower the sUA level for the majority of patients. Dosage of urate-lowering drugs can be reduced if low-purine diet is combined 3 B 8.80 AE 0.93 14 Lifestyle and dietary recommendations for gout patients: maintain healthy weight and waistline, increase physical activity to a moderate level, stay hydrated, and avoid alcoholic and sweetened beverages, as well as animal-derived high purine foods such as internal organs and seafood 3 B 9.10 AE 0.77
LoE: The level of evidence (LOE) and grade of recommendation (GOR) were scored using the Oxford Centre for Evidence-based Medicine Level of Evidence (Oxford Centre for Evidence-Based Medicine: levels of evidence, 2011). 5 [Accessed 10 March, 2016]. Available from URL: http://www.ceb m.net/index.aspx?o=5653. Agreement relates to the entire statement for each recommendation and was voted on a scale from 0 to 10 (0, completely disagree; 10, fully agree). sUA, serum uric acid; MSU, monosodium urate. raise levels of free fatty acids and result in acute gouty attack. Soy bean products generally do not have a high-purine content and thus have little or no effect on sUA levels. In summary, gout patients should avoid consuming high-purine foods such as animal internal organs, seafood and alcohol, especially beer. Moderate consumption of beans and peas has been shown to be safe among gout patients, unless they have previously provoked gout attacks in the individual.
Lifestyle and dietary recommendations for gout patients
• Maintain healthy weight and waistline • Increase physical activity to a moderate level • Stay hydrated • Avoid alcoholic and sweetened beverages, as well as animal-derived high purine foods such as internal organs and seafood (Table 5) . 39, 60 (LoE: 3; GoR: B; Agreement: 9.10 AE 0.77) Aggressive weight loss measures such as fasting may cause massive cell disruption and subsequent uric acid production, thereby triggering gout flares. Therefore, gradual weight loss at the rate of 1 kg/month is appropriate for overweight patients. As a significant correlation between increased physical activity and reduced mortality in hyperuricemic patients has been demonstrated, patients should be advised to exercise moderately and effectively. 61 Dehydration may provoke gout flares; 30, 62, 63 nonetheless, sUA level can usually be restored to normal ranges within 3-4 days with proper rehydration. 64 Maintaining hydration is a key measure in preventing gout attacks, acute gout flares induced by antineoplastic chemotherapy, or MSU crystal formation. 64 Table 6 summarizes the consensus statement of 14 recommendations for the treatment of gout.
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